SunTrust Robinson Reiterates $40.0 Price Objective On Exelixis (EXEL), Reiterates Buy Rating; Nuveen California Municipal Value Fund Has 1.08 Sentiment

January 22, 2018 - By Shannon Black

It closed at $10.11 lastly. It is down 5.82% since January 22, 2017 and is downtrending. It has underperformed by 22.52% the S&P500.

Among 11 analysts covering Exelixis (NASDAQ:EXEL), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Exelixis has $39.0 highest and $15 lowest target. $31.86’s average target is 10.09% above currents $28.94 stock price. Exelixis had 37 analyst reports since January 19, 2016 according to SRatingsIntel. Deutsche Bank initiated it with “Buy” rating and $17 target in Thursday, November 3 report. The firm earned “Buy” rating on Thursday, September 15 by Stifel Nicolaus. The firm earned “Market Perform” rating on Friday, September 22 by Leerink Swann. The stock of Exelixis, Inc. (NASDAQ:EXEL) has “Buy” rating given on Monday, October 16 by RBC Capital Markets. The rating was maintained by Oppenheimer with “Hold” on Thursday, August 3. On Monday, April 4 the stock rating was upgraded by Stifel Nicolaus to “Buy”. The stock of Exelixis, Inc. (NASDAQ:EXEL) has “Hold” rating given on Monday, June 12 by Oppenheimer. Piper Jaffray maintained Exelixis, Inc. (NASDAQ:EXEL) on Thursday, January 4 with “Buy” rating. The stock of Exelixis, Inc. (NASDAQ:EXEL) has “Buy” rating given on Monday, October 16 by Needham. The stock of Exelixis, Inc. (NASDAQ:EXEL) earned “Buy” rating by William Blair on Wednesday, June 14.

Analysts await Exelixis, Inc. (NASDAQ:EXEL) to report earnings on February, 26. They expect $0.12 earnings per share, 0.00% or $0.00 from last year’s $0.12 per share. EXEL’s profit will be $35.50 million for 60.29 P/E if the $0.12 EPS becomes a reality. After $0.26 actual earnings per share reported by Exelixis, Inc. for the previous quarter, Wall Street now forecasts -53.85% negative EPS growth.

Investors sentiment decreased to 1.23 in 2017 Q3. Its down 0.10, from 1.33 in 2017Q2. It is negative, as 39 investors sold Exelixis, Inc. shares while 64 reduced holdings. 51 funds opened positions while 76 raised stakes. 237.25 million shares or 3.37% more from 229.51 million shares in 2017Q2 were reported. Rhumbline Advisers holds 335,781 shares or 0.02% of its portfolio. Los Angeles Cap Equity Rech holds 0.02% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL) for 124,352 shares. Piermont Capital has invested 0.12% in Exelixis, Inc. (NASDAQ:EXEL). Baker Bros Advsr Lp has 0.41% invested in Exelixis, Inc. (NASDAQ:EXEL). Amalgamated National Bank & Trust holds 54,644 shares or 0.04% of its portfolio. Asset Mgmt Inc reported 13,035 shares. Assetmark Inc has 10 shares. Schroder Invest Mngmt Group holds 13,785 shares or 0% of its portfolio. The New York-based Bnp Paribas Arbitrage has invested 0% in Exelixis, Inc. (NASDAQ:EXEL). Wells Fargo & Mn invested 0.02% in Exelixis, Inc. (NASDAQ:EXEL). Axa holds 200,400 shares or 0.02% of its portfolio. 3,232 were reported by Us Bank & Trust De. Comerica Bancorporation holds 11,227 shares or 0% of its portfolio. Jennison Associates Ltd Liability stated it has 0.08% in Exelixis, Inc. (NASDAQ:EXEL). Pillar Pacific Cap Management Ltd Liability Corporation holds 0.06% or 18,000 shares in its portfolio.

Since September 12, 2017, it had 0 insider purchases, and 9 selling transactions for $24.37 million activity. PAPADOPOULOS STELIOS had sold 10,000 shares worth $254,000. On Tuesday, September 26 Schwab Gisela sold $2.38M worth of Exelixis, Inc. (NASDAQ:EXEL) or 100,000 shares. On Thursday, September 14 the insider Haley Patrick J. sold $1.65M. On Wednesday, September 27 the insider Hessekiel Jeffrey sold $663,018. 15,000 shares were sold by Garber Alan M, worth $454,515 on Monday, January 8. WILLSEY LANCE also sold $2.69M worth of Exelixis, Inc. (NASDAQ:EXEL) shares. Another trade for 300,000 shares valued at $8.07M was sold by MORRISSEY MICHAEL.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $8.56 billion. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 59.06 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.